sialorrhea

Summary

Summary: Increased salivary flow.

Top Publications

  1. ncbi A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease
    William G Ondo
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 62:37-40. 2004
  2. ncbi Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial
    Peter H Jongerius
    Department of Rehabilitation, University Medical Centre St Radboud, PO Box 9101 6500HB, Nijmegen 720, Netherlands
    Pediatrics 114:620-7. 2004
  3. ncbi Botulinum toxin injections for children with excessive drooling
    Sharon Hassin-Baer
    Department of Neurology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Child Neurol 20:120-3. 2005
  4. ncbi Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders
    S M Reid
    Developmental Disability Research, Murdoch Childrens Research Institute, University of Melbourne, Victoria, Australia
    Dev Med Child Neurol 50:123-8. 2008
  5. ncbi Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study
    Giovanni Lagalla
    Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Universita Politecnica delle Marche, Az Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Mov Disord 21:704-7. 2006
  6. ncbi Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
    Francesca Mancini
    Parkinson s Disease and Movement Disorders Unit, C Mondino Institute of Neurology, IRCCS, Pavia, Italy
    Mov Disord 18:685-8. 2003
  7. doi Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy
    Yu Ching Lin
    Department of Physical Medicine and Rehabilitation, E Da Hospital, Kaohsiung, Taiwan, ROC
    Neurology 70:316-8. 2008
  8. ncbi Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study
    Chih Sung Liang
    Department of Psychiatry, Beitou Armed Forces Hospital, 60 Shin Ming Road, Beitou, Taipei, Taiwan
    Schizophr Res 119:138-44. 2010
  9. ncbi Drooling, saliva production, and swallowing in cerebral palsy
    Jill E Senner
    Communication Sciences and Disorders, Northwestern University, Evanston, IL 60208, USA
    Dev Med Child Neurol 46:801-6. 2004
  10. ncbi Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement
    D Reddihough
    Developmental Medicine, Royal Children s Hospital, Parkville, Victoria, Australia
    Eur J Neurol 17:109-21. 2010

Detail Information

Publications209 found, 100 shown here

  1. ncbi A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease
    William G Ondo
    Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 62:37-40. 2004
    Injections of botulinum toxin A are an effective treatment for sialorrhea in Parkinson's disease (PD)...
  2. ncbi Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial
    Peter H Jongerius
    Department of Rehabilitation, University Medical Centre St Radboud, PO Box 9101 6500HB, Nijmegen 720, Netherlands
    Pediatrics 114:620-7. 2004
    ..To investigate the clinical effectiveness of botulinum neurotoxin type A (BoNT) to reduce drooling in children with cerebral palsy (CP)...
  3. ncbi Botulinum toxin injections for children with excessive drooling
    Sharon Hassin-Baer
    Department of Neurology, Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Child Neurol 20:120-3. 2005
    ..ultrasonography-guided injections of botulinum toxin A into the parotid glands of children with severe drooling (sialorrhea). Excessive drooling is common in children with chronic neurologic disorders...
  4. ncbi Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders
    S M Reid
    Developmental Disability Research, Murdoch Childrens Research Institute, University of Melbourne, Victoria, Australia
    Dev Med Child Neurol 50:123-8. 2008
    ..While the use of BoNT-A can help to manage drooling in many children with neurological disorders, further research is needed to fully understand the range of responses...
  5. ncbi Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study
    Giovanni Lagalla
    Clinica di Neuroriabilitazione, Dipartimento di Neuroscienze, Universita Politecnica delle Marche, Az Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
    Mov Disord 21:704-7. 2006
    To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive ..
  6. ncbi Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism
    Francesca Mancini
    Parkinson s Disease and Movement Disorders Unit, C Mondino Institute of Neurology, IRCCS, Pavia, Italy
    Mov Disord 18:685-8. 2003
    ..No side effects were observed in either group. BTX injection into parotids and submandibular glands, under ultrasonographic guidance, is an effective and safe treatment for drooling in parkinsonism...
  7. doi Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy
    Yu Ching Lin
    Department of Physical Medicine and Rehabilitation, E Da Hospital, Kaohsiung, Taiwan, ROC
    Neurology 70:316-8. 2008
  8. ncbi Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study
    Chih Sung Liang
    Department of Psychiatry, Beitou Armed Forces Hospital, 60 Shin Ming Road, Beitou, Taipei, Taiwan
    Schizophr Res 119:138-44. 2010
    Clozapine-induced sialorrhea (CIS) is a subjective distressing adverse effect and occurs in 31%-57% of schizophrenic patients receiving clozapine therapy...
  9. ncbi Drooling, saliva production, and swallowing in cerebral palsy
    Jill E Senner
    Communication Sciences and Disorders, Northwestern University, Evanston, IL 60208, USA
    Dev Med Child Neurol 46:801-6. 2004
    ..82,p<0.0001). These findings suggest that drooling in patients with CP is related to swallowing difficulties rather than hypersalivation...
  10. ncbi Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement
    D Reddihough
    Developmental Medicine, Royal Children s Hospital, Parkville, Victoria, Australia
    Eur J Neurol 17:109-21. 2010
    ..BoNT-A is usually well tolerated, although potential side effects should be discussed with the patient and carer...
  11. ncbi Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial
    Ali H Alrefai
    Jordan University of Science and Technology, Jordan
    Clin Neurol Neurosurg 111:79-82. 2009
    To prospectively study the efficacy and safety of intraparotid gland injection of Botulinum neurotoxin serotype A (Dysport) for the treatment of sialorrhea (drooling) in children with cerebral palsy (CP).
  12. ncbi Management of drooling in children
    C B R Fairhurst
    Department of Paediatric Neurosciences, Evelina Children s Hospital, Guy s and Saint Thomas Foundation NHS Trust, Lambeth Palace Road, London SE1 7EH, UK
    Arch Dis Child Educ Pract Ed 96:25-30. 2011
    ..Medically, the focus is on modifying the neuroglandular control of saliva with the use of anticholinergic agents. The article covers these areas of background, assessment and management in detail...
  13. ncbi Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort
    S Perez-Lloret
    Department of Clinical Pharmacology, University Hospital and University of Toulouse, Toulouse, France
    Eur J Neurol 19:28-37. 2012
    Abnormal oro-buccal functions including dysarthria, sialorrhea and dysphagia commonly affect patients with Parkinson's disease (PD).
  14. ncbi Clinical assessment of dysphagia in early phases of Parkinson's disease
    M A Volonte
    Neuroscience Department, University of Milan, IRCCS San Raffaele, Milan, Italy
    Neurol Sci 23:S121-2. 2002
    ..for food and complaints of food sticking in the throat, wet voice and cough after liquid intake and nocturnal sialorrhea were reported, respectively, by 35%, 20% and 15% of patients...
  15. ncbi A randomized trial of botulinum toxin A for treatment of drooling
    A Lipp
    Department of Neurology, Medical Faculty of the Charite, Humboldt University, Berlin, Germany
    Neurology 61:1279-81. 2003
    ..gland) of botulinum toxin A (BTX-A; Dysport, Ipsen Pharma, Germany) injections vs vehicle in patients with sialorrhea (n = 32) using a single-center, prospective, double-blind, placebo-controlled dose-finding study...
  16. ncbi Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial
    Robert Chinnapongse
    US WorldMeds, LLC, Louisville, Kentucky 40207, USA
    Mov Disord 27:219-26. 2012
    b>Sialorrhea (drooling) is a common symptom of Parkinson's disease (PD) that can significantly impair a patient's health and quality of life...
  17. ncbi Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial
    M E L Arbouw
    Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands
    Neurology 74:1203-7. 2010
    b>Sialorrhea affects approximately 75% of patients with Parkinson disease (PD). Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness...
  18. ncbi Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies
    Maik Ellies
    Department of Otorhinolaryngology, Head and Neck Surgery, University of Gottingen, Gottingen, Germany
    J Oral Maxillofac Surg 61:454-7. 2003
    ..We also present a controlled follow-up study documenting efficiency, possible adverse events, and duration of the effect of treatment...
  19. ncbi Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report
    S Glickman
    Rayners Hedge Neuro rehabilitation Unit, Aylesbury Vale Healthcare Community NHS Trust, Aylesbury, London, UK
    Eur J Neurol 8:567-71. 2001
    ..Included also is a case report which is intended to provide an illustration of the benefits of using this method for treating this condition...
  20. pmc Management of drooling in disabled patients with scopolamine patches
    Abigail Mato
    Special Needs Department, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain
    Br J Clin Pharmacol 69:684-8. 2010
    ..To evaluate the efficacy of scopolamine administered transdermally for the treatment of drooling in severely disabled patients...
  21. ncbi Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease
    Marian L Evatt
    Section of Movement Disorders, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    Mov Disord 24:635-46. 2009
    Upper and lower gastrointestinal dysautonomia symptoms (GIDS)--sialorrhea, dysphagia, and constipation are common in Parkinson's disease (PD) and often socially as well as physically disabling for patients...
  22. ncbi Drooling
    Crispian Scully
    Eastman Dental Institute, University College London, London, UK
    J Oral Pathol Med 38:321-7. 2009
    ..Drooling can lead to functional and clinical consequences for patients, families, and caregivers. The aim of this review is to emphasize the clinical aspects of the assessing and management of drooling...
  23. ncbi Systemic manifestations during eruption of primary teeth in infants
    Benjamin Peretz
    Department of Pediatric Dentistry, Hebrew University Hadassah School of Dental Medicine, Jerusalem, Israel
    J Dent Child (Chic) 70:170-3. 2003
    ..The purpose of this study was to describe the most frequent objective clinical manifestations found during the eruption of primary teeth and to assess the correlation between those symptoms and the eruption of various groups of teeth...
  24. ncbi Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease
    Teri R Thomsen
    Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 22:2268-73. 2007
    b>Sialorrhea is a significant problem in advanced Parkinson's disease (PD). Current treatment options include systemic anticholinergics which frequently cause side effects...
  25. ncbi Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B
    B Wilken
    Department of Pediatric Neurology, Klinikum Kassel, Kassel, Germany
    Neuropediatrics 39:200-4. 2008
    ..Botulinum toxin could be a successful option to reduce excessive sialorrhea in children with neurological disorders...
  26. ncbi Glycopyrrolate oral solution: for chronic, severe drooling in pediatric patients with neurologic conditions
    Karly P Garnock-Jones
    Adis, Auckland, New Zealand
    Paediatr Drugs 14:263-9. 2012
    Chronic drooling (sialorrhea) is a common dysfunction in children with neurologic disorders such as cerebral palsy...
  27. ncbi A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients
    Santiago Perez Lloret
    Movement Disorders Section, Raul Carrea Institute for Neurological Research FLENI, Buenos Aires, Argentina
    J Neurol Sci 310:248-50. 2011
    This proof-of-concept, pilot study aimed to explore the safety and anti-sialorrhea efficacy of single doses of intra-oral slow dissolving thin films containing tropicamide (NH004) or placebo.
  28. ncbi Botulinum toxin type A on oral health in treating sialorrhea in children with cerebral palsy: a randomized, double-blind, placebo-controlled study
    Katie Pei Hsuan Wu
    Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    J Child Neurol 26:838-43. 2011
    Intrasalivary gland injection of botulinum toxin type A is known to treat sialorrhea effectively in children with cerebral palsy. However, oral health may be compromised with escalating dose...
  29. ncbi Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelopmental disability: a systematic review
    Kate Rodwell
    Queensland Paediatric Rehabilitation Service, The Royal Children s Hospital, Herston, Brisbane, Australia
    Dev Med Child Neurol 54:977-87. 2012
    ..The aim of this paper was to systematically review the efficacy and safety of botulinum toxin (BoNT) injections to the salivary glands to treat drooling in children with cerebral palsy and neurodevelopmental disability...
  30. ncbi The management of drooling in adults with neurological conditions
    Nina Squires
    Speech and Language Therapy Department, Queen s Medical Centre, Nottingham, UK
    Curr Opin Otolaryngol Head Neck Surg 20:171-6. 2012
    ..This review will consider the physical and psychosocial impact of drooling and will discuss the current management options including behavioural, pharmacological and surgical approaches...
  31. ncbi Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: a review
    Domenico Intiso
    Neuro rehabilitation Unit, Scientific Institute, Hospital IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    NeuroRehabilitation 31:117-29. 2012
    ..of BTX use in treating muscular imbalance of children with obstetrical brachial plexus palsy and in reducing sialorrhea following neurological diseases including amyotrophic lateral sclerosis (ASL), Parkinson disease and cerebral ..
  32. ncbi Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study
    H Christopher Hyson
    Movement Disorders Program, London Health Sciences Centre, London, Ontario, Canada
    Mov Disord 17:1318-20. 2002
    b>Sialorrhea is a relatively common symptom in idiopathic Parkinson's disease and related conditions for which most of the accepted treatments are either highly invasive or may cause substantial systemic side effects...
  33. ncbi Botulinum toxin for the treatment of sialorrhea: a meta-analysis
    Rishi Vashishta
    Department of Otolaryngology Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Otolaryngol Head Neck Surg 148:191-6. 2013
    Botulinum toxin has emerged as an effective approach for the management of sialorrhea. This study presents a critical literature review and meta-analysis to determine the impact of botulinum toxin on drooling severity in patients with ..
  34. ncbi [Sialorrhea, hyperhidrosis and botulinum toxin]
    G Monnier
    Explorations et pathologies neuromusculaires, CHU Jean Minjoz, 3, Boulevard Fleming, 25030 Besancon Cedex, France
    Ann Readapt Med Phys 46:338-45. 2003
    The first clinical studies indicate that Botox provides effective treatment for hyperhidrosis and sialorrhea. The aim of this work is to sum up current evaluation of this use.
  35. ncbi Silent aspiration in Parkinson's disease patients with diurnal sialorrhea
    Ana Caline Nóbrega
    Division of Neurology and Epidemiology, Federal University of Bahia, Brazil
    Clin Neurol Neurosurg 110:117-9. 2008
    We studied the frequency of silent laryngeal penetration or silent aspiration (SLP/SA) in Parkinson's disease (PD) patients with diurnal sialorrhea.
  36. ncbi The management of drooling in motor neurone disease
    Pauline Dand
    Pilgrims Hospices, East Kent, Canterbury, Kent, United Kingdom
    Int J Palliat Nurs 16:560-4. 2010
    ..Further research needs to explore ways of enhancing swallowing ability as well as ways of optimizing drug therapies...
  37. ncbi Self-management treatment of drooling: a case series
    J J W Van der Burg
    Department of Special Education, Radboud University Nijmegen, P O Box 9104, 6500 HE Nijmegen, The Netherlands
    J Behav Ther Exp Psychiatry 40:106-19. 2009
    ..Seven participants failed to maintain self-management skills at follow-up. Although the self-management procedure showed promising results, further adaptations are required to improve efficacy, generalization, and maintenance...
  38. ncbi Success and complications of four-duct ligation for sialorrhea
    W Peyton Shirley
    Department of Pediatric Otolaryngology, Children s Hospital of Alabama, 1600 Seventh Avenue South ACC320, Birmingham, AL 35233, USA
    Int J Pediatr Otorhinolaryngol 67:1-6. 2003
    b>Sialorrhea can have a significant negative effect on quality of life, impeding social interactions and severely limiting employment opportunities. Many surgical options to control sialorrhea have been reported...
  39. ncbi Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Ana Caline Nóbrega
    Division of Neurology and Epidemiology, Federal University of Bahia, Brazil
    J Neurol Sci 253:85-7. 2007
    ..Future trials assessing the level of swallowing dysfunction may be important to establish a prognosis for patients who keep the frequency of drooling in spite of decreased severity after BTX injection...
  40. ncbi Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease
    Okan Dogu
    Department of Neurology, Faculty of Medicine, Tip Fakultesi Hastanesi, Noroloji Anabilim Dali, Zeytinlibahce Cad, Mersin Universitesi, 33070 Mersin, Turkey
    Clin Neurol Neurosurg 106:93-6. 2004
    ..To investigate the efficacy and safety of intraparotid botulinum toxin-A (BTX-A) injections into parotid gland using ultrasound-guided versus nonguided techniques for the treatment of sialorrhoea in patients with Parkinson's disease (PD)...
  41. ncbi Is drooling secondary to a swallowing disorder in patients with Parkinson's disease?
    Ana Caline Nóbrega
    Division of Neurology and Epidemiology, Federal University of Bahia, Brazil
    Parkinsonism Relat Disord 14:243-5. 2008
    ..Previous studies point to an association between swallowing problems and sialorrhea. The aim of this study was to determine if drooling is associated with dysphagia in PD patients...
  42. ncbi Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling
    Giovanni Lagalla
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita Politecnica delle Marche, Ospedali Riuniti, Ancona, Italy
    J Neurol 256:563-7. 2009
    ..To investigate the safety, efficacy and effectiveness of botulinum toxin type-B (BTX-B) injections into the parotid glands to reduce drooling in Parkinson's disease (PD) subjects...
  43. ncbi Sialorrhea: a management challenge
    Neil G Hockstein
    Department of Otolaryngology Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am Fam Physician 69:2628-34. 2004
    b>Sialorrhea (drooling or excessive salivation) is a common problem in neurologically impaired children (i.e., those with mental retardation or cerebral palsy) and in adults who have Parkinson's disease or have had a stroke...
  44. ncbi Impact of drooling in Parkinson's disease
    Johanna G Kalf
    Dept of Allied Health Occupations, Speech Language Therapy, Nijmegen, The Netherlands
    J Neurol 254:1227-32. 2007
    ..History taking ought to be detailed and specific to understand the full impact of drooling for an individual patient. Therapeutic options should be evaluated more intensively...
  45. pmc Prevalence and definition of drooling in Parkinson's disease: a systematic review
    J G Kalf
    Department of Rehabilitation, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands
    J Neurol 256:1391-6. 2009
    ..In about a quarter of PD patients, drooling appears to be a frequently occurring problem. We recommend to report drooling in future studies with more detailed consideration of severity, frequency and nocturnal versus diurnal complaints...
  46. ncbi Sialorrhea - therapeutic drug options
    Dorothy Z Tscheng
    Drug Information and Research Centre, Ontario Pharmacists Association, Don Mills, Ontario, Canada
    Ann Pharmacother 36:1785-90. 2002
    To review the efficacy and safety of various drug treatments for sialorrhea. Pharmacotherapy for drug-induced sialorrhea is not addressed.
  47. ncbi Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease
    Arianna Guidubaldi
    Istituto di Neurologia, Universita Cattolica del Sacro Cuore, Roma, Italia
    Mov Disord 26:313-9. 2011
    ..Either botulinum toxins (BoNTs) A and B have been used for improving drooling in different neurological conditions...
  48. ncbi Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy
    Dana L Suskind
    Department of Otolaryngology, LSU School of Medicine and Children s Hospital of New Orleans, New Orleans, Louisiana, U S A
    Laryngoscope 112:73-81. 2002
    To assess the safety and efficacy of intraglandular (parotid and submandibular) botulinum-A toxin (BTX-A) in the treatment of sialorrhea in children with cerebral palsy (CP).
  49. ncbi Botulinum toxin A as a treatment for excessive drooling in children
    J E Bothwell
    Department of Pediatrics, Division of Pediatric Neurology, IWK Health Centre, Halifax, Nova Scotia, Canada
    Pediatr Neurol 27:18-22. 2002
    ..Overall, five of nine parents (55%) deemed the treatment successful. This preliminary study demonstrates that botulinum toxin A is a relatively effective treatment for some children with significant drooling without serious side effects...
  50. ncbi Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study
    R J Mier
    Shriners Hospital for Children, 1900 Richmond Rd, Lexington, KY 40502, USA
    Arch Pediatr Adolesc Med 154:1214-8. 2000
    To determine the safety and efficacy of glycopyrrolate in the treatment of developmentally disabled children with sialorrhea.
  51. ncbi Symptoms associated with infant teething: a prospective study
    M L Macknin
    Departments of Pediatrics and Adolescent Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Pediatrics 105:747-52. 2000
    ..Studies of infant teething have been retrospective, small, or conducted on institutionalized infants...
  52. ncbi The cause of drooling in children with cerebral palsy -- hypersalivation or swallowing defect?
    J F Tahmassebi
    Department of Paediatric Dentistry, Leeds Dental Institute, Leeds, UK
    Int J Paediatr Dent 13:106-11. 2003
    ..To determine whether or not drooling in children with cerebral palsy is due to hypersalivation...
  53. ncbi The treatment of drooling by ultrasound-guided intraglandular injections of botulinum toxin type A into the salivary glands
    Peter H Jongerius
    Department of Rehabilitation, University Medical Center St Radboud, Nijmegen, The Netherlands
    Laryngoscope 113:107-11. 2003
    ..The aim of the study was to present the background, procedure, and technique of bilateral ultrasound-guided, single-dose injections of botulinum toxin type A (BTX) into the salivary glands in patients with severe drooling...
  54. ncbi Glycopyrrolate for clozapine-induced sialorrhea
    Harpreet S Duggal
    Prog Neuropsychopharmacol Biol Psychiatry 31:1546-7. 2007
  55. ncbi Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy
    Robert Savarese
    Department of Physical Medicine and Rehabilitation, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07091, USA
    Am J Phys Med Rehabil 83:304-11; quiz 312-4, 336. 2004
    To determine the efficacy of botulinum toxin A in the management of drooling (sialorrhea) in children and young adults with cerebral palsy.
  56. ncbi The impact of and the factors associated with drooling in Parkinson's disease
    Joshua Leibner
    College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Parkinsonism Relat Disord 16:475-7. 2010
    ..Experiencing hallucinations was the only factor that correlated with being a drooler and it may be confounded by medications...
  57. pmc Evaluation and management of sialorrhea of pregnancy with concomitant hyperemesis
    J J Freeman
    Nassau County Department of Health, Hempstead, New York
    J Natl Med Assoc 86:704-8. 1994
    This article describes two gravid patients who presented with first-trimester sialorrhea and hyperemesis...
  58. ncbi Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease
    H Worth Boyce
    Joy McCann Culverhouse Center for Swallowing Disorders, University of South Florida College of Medicine, Tampa, FL 33612, USA
    J Clin Gastroenterol 39:89-97. 2005
    ..On the other hand, sialorrhea or ptyalism, the condition of increased salivary flow, is rarely discussed in the clinical literature...
  59. ncbi Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis
    Carol A Stone
    Our Lady s Hospice, Dublin, Ireland
    J Pain Symptom Manage 37:246-58. 2009
    ..lateral sclerosis (ALS) experience problems handling serous saliva and 20% fail to achieve adequate control of sialorrhea with anticholinergic medications, or experience intolerable adverse effects from these drugs...
  60. ncbi Is clonidine useful for treatment of clozapine-induced sialorrhea?
    Samir Kumar Praharaj
    Senior Resident, Department of Psychiatry, Dr Ram Manohar Lohia Hospital, New Delhi, India
    J Psychopharmacol 19:426-8. 2005
    ..Among other adverse effects, sialorrhea is a troublesome side-effect, its stigmatizing nature results in poor treatment compliance...
  61. ncbi Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations
    E K Tan
    Department of Neurology, Singapore General Hospital, National Neuroscience Institute, Division of Research, SingHealth
    Eur J Neurol 13:60-4. 2006
    ..a number of potential new therapeutic indications of botulinum toxin injections have emerged, amongst which sialorrhea has attracted considerable attention...
  62. ncbi Botulinum toxin A in the treatment of sialorrhea
    Jennifer Benson
    Kroger Pharmacy, Frankenmuth, MI, USA
    Ann Pharmacother 41:79-85. 2007
    To review the efficacy and safety of botulinum toxin A (BTX) in the treatment of sialorrhea.
  63. ncbi Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis
    Joao Costa
    Serviço de Neurologia Piso 7, Hospital de Santa Maria, Av Prof Egas Moniz, 1649 035 Lisboa
    J Neurol 255:545-50. 2008
    b>Sialorrhea is a disabling problem in bulbaronset amyotrophic lateral sclerosis (ALS). Botulinum toxin (BTX) type A and B have been proposed as alternatives to traditional treatments.
  64. ncbi Long-term efficacy of intra-oral surgery for sialorrhea
    Timothy J Martin
    Department of Otolaryngology, Division of Pediatric Otolaryngology, Children s Hospital of Wisconsin, Medical College of WI, Milwaukee, WI 53226, USA
    Otolaryngol Head Neck Surg 137:54-8. 2007
    To investigate the efficacy and quality of life impact of intra-oral surgery for sialorrhea and to provide long-term outcome measures.
  65. ncbi Salivary gland application of botulinum toxin for the treatment of sialorrhea
    María Angeles Fuster Torres
    University of Barcelona Dental School, Barcelona, Spain
    Med Oral Patol Oral Cir Bucal 12:E511-7. 2007
    b>Sialorrhea or excessive salivation, and drooling, are common and disabling manifestations in different neurological disorders...
  66. ncbi Teething symptoms in the first year of life and associated factors: a cohort study
    Carlos Alberto Feldens
    Department of Pediatric Dentistry, Universidade Luterana do Brasil, Canoas, Brazil
    J Clin Pediatr Dent 34:201-6. 2010
    ..To investigate the occurrence and management of teething symptoms during the first year of life and associated factors...
  67. ncbi Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism
    Anna Gerlind Postma
    Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Mov Disord 22:2430-5. 2007
    ..the long-term efficacy and safety of radiotherapy (RT) to the major salivary glands as treatment of sialorrhea in patients with parkinsonism...
  68. ncbi Botulinum toxin versus submandibular duct relocation for severe drooling
    Arthur R T Scheffer
    Department of Otorhinolaryngology and Head and Neck Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
    Dev Med Child Neurol 52:1038-42. 2010
    ..However, its effectiveness compared with established treatments is still unknown. We undertook a within-participants observational study to examine this...
  69. ncbi Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients
    Carlayne E Jackson
    University of Texas Health Science Center, 7703 Floyd Curl Drive, Mail Code 7883, San Antonio, Texas 78229 3900, USA
    Muscle Nerve 39:137-43. 2009
    Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular ..
  70. ncbi Efficacy and duration of botulinum toxin treatment for drooling in 131 children
    Arthur R T Scheffer
    Department of Otorhinolaryngology Head and Neck Surgery, Radboud University Medical Center, Nijmegen 6525EX, The Netherlands
    Arch Otolaryngol Head Neck Surg 136:873-7. 2010
    ..To address the efficacy of botulinum toxin and the duration of its effect when used on a large scale for the treatment of drooling in children with neurological disorders...
  71. ncbi Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease
    James K Sheffield
    Department of Neurology, Baylor College of Medicine, Parkinson s Disease Center and Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Expert Rev Neurother 7:637-47. 2007
    ..and jaw tremor, dystonia, blepharospasm and apraxia of eyelid opening, bruxism, camptocormia, freezing of gait, sialorrhea and constipation...
  72. ncbi Sialorrhea in Parkinson's disease: a review
    Kelvin L Chou
    Department of Clinical Neurosciences, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
    Mov Disord 22:2306-13. 2007
    A significant number of patients with Parkinson's disease (PD) experience sialorrhea. This problem can cause social embarrassment, and because saliva pools in the mouth, may lead to aspiration pneumonia...
  73. ncbi [Treatment with botulinum toxin in neurologic pediatrics]
    Nicole Justus
    Kinderkrankenschwester, Muchen
    Kinderkrankenschwester 26:274-6. 2007
  74. ncbi [The current approach to hyper-sialorrhea]
    William Defossez
    Chirurgie Maxillo Faciale, Imeldaziekenhuis 2820 Bonheiden, AZ Jan Portaels 1800, Vilvoorde
    Rev Belge Med Dent (1984) 61:173-9. 2006
    Drooling (sialorrhea or excessive salivation) is a common problem in neurologically impaired children and in adults who have Parkinson-disease...
  75. ncbi Drooling: analysis and evaluation of 31 children who underwent bilateral submandibular gland excision and parotid duct ligation
    Dayse Manrique
    ENT Department, UNIFESP, Sao Paulo, SP, Brazil
    Braz J Otorhinolaryngol 73:40-4. 2007
    ..To evaluate the safety of bilateral submandibular gland excision and parotid duct ligation in order to control drooling in children; to assess its long-term efficacy and complications...
  76. pmc Is injection of botulinum toxin type A effective in the treatment of drooling in children with cerebral palsy?
    L Vaile
    Community Child Health, NHS House, Newbridge Hill, Bath BA1 3QE, UK
    Arch Dis Child 91:862-3. 2006
  77. ncbi Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy
    K J Banerjee
    Department of Rehabilitation, The Children s Hospital at Westmead, Sydney, Australia
    Dev Med Child Neurol 48:883-7. 2006
    ..We conclude that percutaneous intrasalivary BTX-A injections into the parotid and submandibular salivary glands can reduce drooling in children with CP and relative sialorrhoea, leading to an improvement in their quality of life...
  78. ncbi Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence
    Luke Molloy
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Curr Opin Neurol 20:493-8. 2007
    ..3) Recent studies suggest that botulinum toxin injection is currently the most effective treatment option for Parkinsonian-related sialorrhoea...
  79. ncbi Clinical prevalence of drooling in infant cerebral palsy
    Mariana Carolina Morales Chávez
    Department of Stomatology, Valencia University, Dr Peset University Hospital, Valencia, Spain
    Med Oral Patol Oral Cir Bucal 13:E22-6. 2008
    ..To determine the prevalence and severity of drooling in infant cerebral palsy (ICP) and analyze the possible surgical, pharmacological, myofunctional and novel alternative approaches to treatment of this disorder...
  80. ncbi Efficacy of relocation of submandibular duct in cerebral palsy patients with drooling
    Periyanan Puraviappan
    Department of ENT, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
    Asian J Surg 30:209-15. 2007
    ..The efficacy of relocating the submandibular duct to treat drooling in children with cerebral palsy was studied...
  81. ncbi Ultrasound-guided, intraglandular injection of botulinum toxin A in children suffering from excessive salivation
    I Gerlinger
    Department of Otorhinolaryngology and Head and Neck Surgery, University of Pecs, Hungary
    J Laryngol Otol 121:947-51. 2007
    ..The aim of this study was to describe the authors' minimally invasive procedure developed to significantly decrease excessive salivation in children suffering from chronic neurological diseases, using botulinum toxin A...
  82. ncbi Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study
    Subhaschandra Shetty
    Whangarei Base Hospital, Whangarei
    N Z Med J 119:U2129. 2006
    ..We report our initial experience using Botox-A injection to the salivary glands to control sialorrhoea...
  83. ncbi Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis
    E Neppelberg
    Department of Oral and Maxillofacial Surgery, Haukeland University Hospital, Bergen, Norway
    Eur J Neurol 14:1373-7. 2007
    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. Sialorrhea is a frequent problem in ALS patients with bulbar symptoms, because of progressive weakness of oral, lingual and pharyngeal muscles...
  84. ncbi [Botulinium toxin in ENT]
    P Klap
    Service d Oto Rhino Laryngologie et de Chirurgie Cervico faciale, Fondation A de Rothschild, 25 rue Manin, 75019, Paris, France
    Ann Otolaryngol Chir Cervicofac 123:306-11. 2006
  85. ncbi Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands
    Steffen Berweck
    Dr von Hauner s Children s Hospital, University of Munich, Munich, Germany
    Dev Med Child Neurol 49:62-4. 2007
    ..The resulting immune complexes could be taken up by phagocytes and, thereby, impede clinical response...
  86. ncbi The role of botulinum toxin in the management of head and neck cancer patients
    Rainer Laskawi
    Department ORL HNS, University of Gottingen, Gottingen, Germany
    Curr Opin Otolaryngol Head Neck Surg 15:112-6. 2007
    ..In this review article different relevant applications of botulinum toxin type A are demonstrated in patients with head and neck cancer...
  87. ncbi Nonsurgical management of traumatic injuries of the parotid gland and duct using type a botulinum toxin
    Sebastien Arnaud
    Department of Maxillofacial Surgery, Lapeyronie University Hospital, Montpellier, France
    Plast Reconstr Surg 117:2426-30. 2006
  88. ncbi Botulinum toxin effect on salivary flow rate in children with cerebral palsy
    P H Jongerius
    Department of Rehabilitation, University Medical Centre St Radboud, PO Box 9101, 6500HB, Nijmegen 720, The Netherlands
    Neurology 63:1371-5. 2004
    ..To investigate the effectiveness of botulinum neurotoxin (BoNT) type A in reducing salivary flow rate in children with cerebral palsy (CP) with severe drooling...
  89. ncbi Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis
    Maik Ellies
    Department of Otorhinolaryngology Head and Neck Surgery, University of Gottingen, Robert Koch Strasse 40, D 37075 Gottingen, Germany
    Laryngoscope 114:1856-60. 2004
    ..A controlled follow-up study documenting efficiency, possible side effects, and duration of the effect of treatment was also performed...
  90. ncbi Management of Frey's syndrome and hypersialorrhea with botulinum toxin
    Orlando Guntinas-Lichius
    Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, D 50924 Cologne, Germany
    Facial Plast Surg Clin North Am 11:503-13. 2003
    ....
  91. ncbi [Experimental and clinical investigations on the inhibition of secretion of the major salivary glands with botulinum toxin A]
    M Ellies
    HNO Klinik der Georg August Universität Göttingen
    Laryngorhinootologie 82:713-4. 2003
  92. ncbi [Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands]
    F J Carod Artal
    Servicio de Neurologia, Hospital Sarah, Brasilia, Brasil
    Neurologia 18:280-4. 2003
    ..Anticholinergic drugs often produce side effects in these patients. Botulinum toxin A (TBA) blocks liberation of acetil-choline in motor and autonomic nerve terminals...
  93. ncbi Successful management of drooling with botulinum toxin A in neurologically disabled children
    M Ellies
    Department of Otorhinolaryngology, Head and Neck Surgery, University of Gottingen, Gottingen, Germany
    Neuropediatrics 33:327-30. 2002
    ..The present study investigates the effect of topical injections of botulinum toxin A into the cephalic salivary glands of children with chronic hypersalivation due to neurodegenerative diseases...
  94. ncbi Bilateral parotid-duct diversion using autologous vein grafts for the management of chronic drooling in cerebral palsy
    G Y Ozgenel
    Department of Plastic and Reconstructive Surgery, Medical Faculty of Uludag University, Bursa, Turkey
    Br J Plast Surg 55:490-3. 2002
    ....
  95. ncbi Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis
    Ashok Verma
    Department of Neurology, Kessenich Family MDA ALS Center, 1150 NW 14th Street, Suite 701, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Muscle Nerve 34:235-7. 2006
    b>Sialorrhea is frequently a socially disabling symptom in patients with bulbar amyotrophic lateral sclerosis (ALS)...
  96. ncbi Bilateral submandibular gland excision with parotid duct ligation for treatment of sialorrhea in children: long-term results
    Yoram Stern
    Department of Pediatric Otolaryngology, Schneider Children s Medical Center of Israel, 14 Kaplan St, Petah Tiqva 49 202, Israel
    Arch Otolaryngol Head Neck Surg 128:801-3. 2002
    Multiple procedures have been advocated for the surgical control of chronic sialorrhea in children. However, some of them are associated with significant complications or only short-term success.
  97. ncbi Temporary reduction of salivation in laryngectomy patients with pharyngocutaneous fistulas by botulinum toxin A injection
    Orlando Guntinas-Lichius
    Department of Otorhinolaryngology, University of Cologne, D 50925 Koeln, Germany
    Laryngoscope 112:187-9. 2002
  98. ncbi [Botulinum toxin against drooling--not without problems!]
    Hilde Nordgarden
    Tidsskr Nor Laegeforen 128:1985. 2008
  99. ncbi Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders
    Pasquale Capaccio
    Department of Otorhinolaryngological and Ophthalmological Sciences, University of Milan, Policlinico Foundation IRCCS, Milan, Italy
    Am J Otolaryngol 29:333-8. 2008
    ..The aim of the study was to investigate the feasibility and effectiveness of botulinum toxin therapy in salivary secretory disorders...
  100. ncbi Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis
    Jan Willem G Meijer
    Rehab Centre Tolbrug Jeroen Bosch Hospital, s Hertogenbosch, The Netherlands
    Am J Phys Med Rehabil 87:321-4. 2008
    ....
  101. ncbi A review of the current uses of Botox for dentally-related procedures
    Preetpal Sing Bhogal
    Oral and Maxillofacial Surgery, Birmingham Children s Hospital
    Dent Update 33:165-8. 2006
    ....

Research Grants8

  1. AN INTRA-ORAL SALIVA VACUUMING APPLIANCE FOR SIALORRHEA
    Carrie Brown; Fiscal Year: 2000
    b>Sialorrhea (i.e., drooling) is a profound social and hygienic problem for individuals with this condition. Innovative Human Services, Inc...
  2. Cardiac-Related Mortality with Atypical Antipsychotics
    DEANNA KELLY; Fiscal Year: 2005
    ..This study is important as data on long-term health outcomes with atypical antipsychotics is lacking from the literature. ..
  3. Sensory Re-training following Orthognathic Surgery
    Ceib Phillips; Fiscal Year: 2005
    ..Our primary focus will be on the patient's perception of the negative impact of altered sensation on daily life. ..
  4. GENETICS OF PARKINSON DISEASE IN THE AMISH
    Brad Racette; Fiscal Year: 2006
    ..abstract_text> ..
  5. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2008
    ..This will be an important step for improving the lives of people with schizophrenia. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  6. Epidemilogy of Parkinsonism in Welders
    Brad A Racette; Fiscal Year: 2011
    ..The cohort assembled will provide unique opportunities for future research projects into gene-environment interactions and exposure related neuroimaging changes. ..